UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 542

Sortiert nach

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Haematologica (Roma), 2016-06, Vol.101 (6), p.717

2016

Volltextzugriff (PDF)

Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma

Cancer Immunology, Immunotherapy, 2021-01, Vol.70 (1), p.31-45

2021

Volltextzugriff (PDF)

Identification of Cell Type-Specific Effects of DNMT3A Mutations on Relapse in Acute Myeloid Leukemia

Molecules and Cells, 2023, 46(10), , pp.611-626

2023

Volltextzugriff (PDF)

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry

PloS one, 2021-05, Vol.16 (5), p.e0251011-e0251011

2021

Volltextzugriff (PDF)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

BMC cancer, 2020-08, Vol.20 (1), p.803-803, Article 803

2020

Volltextzugriff (PDF)

A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System

British journal of haematology, 2018-06, Vol.181 (5), p.707-710

2018

Volltextzugriff (PDF)

Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21

Cancer Immunology, Immunotherapy, 2022-03, Vol.71 (3), p.613-625

2022

Volltextzugriff (PDF)

Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia

Scientific reports, 2024-04, Vol.14 (1), p.8517-8517, Article 8517

2024

Volltextzugriff (PDF)

FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation

Journal of experimental & clinical cancer research, 2022-03, Vol.41 (1), p.82-82, Article 82

2022

Volltextzugriff (PDF)

Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

Cellular & molecular immunology, 2021-07, Vol.18 (7), p.1652-1661

2021

Volltextzugriff (PDF)

Immunotherapy for the treatment of multiple myeloma

Critical reviews in oncology/hematology, 2017-03, Vol.111, p.87-93

2017

Volltextzugriff (PDF)

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

Frontiers in immunology, 2018-06, Vol.9, p.1370-1370

2018

Volltextzugriff (PDF)

HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

Leukemia, 2019-06, Vol.33 (6), p.1439-1450

2019

Volltextzugriff (PDF)

Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine

Hematology (Luxembourg), 2024-12, Vol.29 (1), p.2324417-2324417

2024

Volltextzugriff (PDF)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD

Cell transplantation, 2022, Vol.31, p.96368972211137-9636897221113789

2022

Volltextzugriff (PDF)

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3472-3479

2009

Volltextzugriff (PDF)

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

British journal of haematology, 2013-05, Vol.161 (3), p.339-347

2013

Volltextzugriff (PDF)

Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing

Bone marrow transplantation (Basingstoke), 2021-05, Vol.56 (5), p.1159-1170

2021

Volltextzugriff (PDF)

Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study

Frontiers in oncology, 2024, Vol.14, p.1307315-1307315

2024

Volltextzugriff (PDF)

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma

BMC cancer, 2019-01, Vol.19 (1), p.59-59, Article 59

2019

Volltextzugriff (PDF)

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

Haematologica (Roma), 2009-01, Vol.94 (1), p.135-139

2009

Volltextzugriff (PDF)

l‐Asparaginase‐mediated downregulation of c‐Myc promotes 1,25(OH)2D3‐induced myeloid differentiation in acute myeloid leukemia cells

International journal of cancer, 2017-05, Vol.140 (10), p.2364-2374

2017

Volltextzugriff (PDF)

A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy

Cellular & molecular immunology, 2021-06, Vol.18 (6), p.1599-1601

2021

Volltextzugriff (PDF)

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

Journal of hematology and oncology, 2022-05, Vol.15 (1), p.56-56, Article 56

2022

Volltextzugriff (PDF)

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

Cancer science, 2010-05, Vol.101 (5), p.1247-1254

2010

Volltextzugriff (PDF)

1 – 25 von 542

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(506)
Mit Volltextzugriff
(527)

Publikationsform

Artikel
(536)
Berichte
(6)

Sprache

Englisch
(511)
Koreanisch
(31)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma

Identification of Cell Type-Specific Effects of DNMT3A Mutations on Relapse in Acute Myeloid Leukemia

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System

Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21

Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia

FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation

Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

Immunotherapy for the treatment of multiple myeloma

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing

Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

l‐Asparaginase‐mediated downregulation of c‐Myc promotes 1,25(OH)2D3‐induced myeloid differentiation in acute myeloid leukemia cells

A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

Suchergebnisse filtern